pneumonia h2012 -chapter 257
DESCRIPTION
Pneumonia H2012 -Chapter 257. Infection of the pulmonary parenchyma Proliferation of microbial pathogens at the alveolar level and the host's response to those pathogens. Most common :aspiration from the oropharynx Many inhaled as contaminated droplets - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/1.jpg)
PneumoniaH2012 -Chapter 257
Infection of the pulmonary parenchyma
Proliferation of microbial pathogens at the alveolar level and the host's
response to those pathogens
![Page 2: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/2.jpg)
Most common :aspiration from the oropharynx
Many inhaled as contaminated droplets
Rarely, hematogenous spread (tricuspid endocarditis)
Contiguous extension from an infected pleural or mediastinal space.
![Page 3: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/3.jpg)
Mechanical factors
Hairs and turbinates of the nares
Branching architecture of the tracheobronchial tree(where mucociliary clearance and local antibacterial factors
either clear or kill)
Gag reflex and Cough
Normal flora of the oropharynx, components are remarkably constant
![Page 4: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/4.jpg)
Macrophages are extremely efficient at clearing and killing pathogens.
Local proteins (e.g., surfactant proteins A and D) have intrinsic opsonizing properties
or antibacterial or antiviral activity
Once engulfed by the macrophage, the pathogens—even if they are not killed—are
eliminated via either the mucociliary elevator or the lymphatics and no longer
represent an infectious challenge
![Page 5: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/5.jpg)
The host inflammatory response, rather than the
proliferation of microorganisms, triggers the clinical syndrome of
pneumonia
![Page 6: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/6.jpg)
Community-Acquired Pneumonia
Bacteria, Fungi, Viruses, Protozoa
Newly :
Hantaviruses, Metapneumoviruses, Coronavirus responsible for severe acute respiratory syndrome (SARS), and community-acquired strains of
methicillin-resistant Staphylococcus aureus (MRSA)
![Page 7: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/7.jpg)
Most Common
Streptococcus Pneumoniae
![Page 8: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/8.jpg)
Typical
Streptococcus Pneumoniae
Haemophilus Influenzae
S. Aureus
Klebsiella Pneumoniae
Pseudomonas Aeruginosa
![Page 9: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/9.jpg)
Atypical(in outpatients)
Mycoplasma pneumoniae
Chlamydia pneumoniae(in inpatients)
Legionella spp
Influenza viruses
Adenoviruses
Respiratory Syncytial Viruses
![Page 10: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/10.jpg)
Atypical organisms
Cannot be cultured on standard media, nor can they be seen on
Gram's stain.
Intrinsically resistant to all β-lactam agents and must be treated with a
Macrolide, Fluoroquinolone, Tetracycline
![Page 11: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/11.jpg)
Virus may be responsible for up to 18% of cases of CAP that require
admission to the hospital
![Page 12: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/12.jpg)
10–15% of CAP
Polymicrobial
often Typical + Atypical
![Page 13: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/13.jpg)
ما ! که ده آن را ما الهیبه آن ! را
![Page 14: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/14.jpg)
Microbial Causes of Community-Acquired Pneumonia, by Site of Care
Outpatients Non-ICU ICUS. pneumoniae S. pneumoniae S. pneumoniae M. pneumoniae M. pneumoniae S. aureus H. influenzae C. Pneumoniae Legionella
C. pneumoniae H. influenzae Gram-negativeRespiratory v.a Legionella H. influenzae
Respiratory virusesa
listed in descending order of frequency
aInfluenza A and B viruses, adenoviruses, respiratory syncytial viruses, parainfluenza viruses
![Page 15: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/15.jpg)
Anaerobes
Only when an episode of aspiration
days to weeks before presentation pneumonia
Alcohol
Drug Overdose
Seizure
Gingivitis
often complicated by abscess formation and significant empyemas or parapneumonic
effusions.
![Page 16: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/16.jpg)
S. aureus
Complicate influenza infection
MRSA reported as the primary etiologic agent of CAP
still relatively uncommon, necrotizing pneumonia
MRSA from hospital to the community
Genetically distinct strains of MRSA in the community
![Page 17: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/17.jpg)
Despite a careful history , physical examination and routine radiographic, the
causative pathogen in a case of CAP is difficult to predict
In more than One-Half of cases, a specific etiology is never determined
Epidemiologic and risk factors may suggest the involvement of certain pathogens
![Page 18: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/18.jpg)
Epidemiologic Factors Suggesting Possible Causes of Community-
Acquired Pneumonia
![Page 19: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/19.jpg)
Alcoholism
Streptococcus pneumoniae
Oral anaerobes
Klebsiella pneumoniae
Acinetobacter spp
Mycobacterium tuberculosis
![Page 20: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/20.jpg)
COPD and/or smoking
Haemophilus influenzae Pseudomonas
aeruginosa
Legionella spp.
S. Pneumoniae
Moraxella catarrhalis
Chlamydia pneumoniae
![Page 21: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/21.jpg)
Risk factors for CAP
Alcoholism
Asthma
Immunosuppression
Institutionalization
≥70 years
![Page 22: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/22.jpg)
Risk factors for pneumococcal pneumonia
Dementia
Seizure disorders
Heart failure
Cerebrovascular disease
Alcoholism
Tobacco smoking
COPD
![Page 23: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/23.jpg)
CA-MRSA Pneumonia
Skin colonization
Infection with CA-MRSA
![Page 24: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/24.jpg)
P. aeruginosa
Bronchiectasis
Cystic fibrosis
Severe COPD
![Page 25: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/25.jpg)
Legionella
Diabetes
Hematologicmalignancy
Cancer
Severe renal disease
HIV infection
Smoking Male
Recent Hotel stay or Ship cruise
![Page 26: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/26.jpg)
Clinical Manifestations
Indolent to Fulminant
Mild to Fatal
Frequently Febrile with Tachycardia
Chills
Sweats
![Page 27: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/27.jpg)
Cough
Nonproductive or Productive
Mucoid, Purulent, Blood-tinged
![Page 28: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/28.jpg)
If the pleura is involved, : Pleuritic Chest Pain
20% : Gastrointestinal symptoms
Nausea, Vomiting, Diarrhea
Other symptoms may include
Fatigue, Headache, Myalgias, Arthralgias
![Page 29: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/29.jpg)
Auscultation
Crackles
Bronchial breath sounds
Pleural friction rub
![Page 30: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/30.jpg)
Diagnosis
1:Is this pneumonia?
Clinical and Radiographic methods
2:what is the likely etiology?
aid of Laboratory techniques
![Page 31: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/31.jpg)
Clinical Diagnosis
Acute bronchitis
Acute exacerbations of chronic bronchitis
Heart failure
Pulmonary embolism
Radiation pneumonitis.
![Page 32: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/32.jpg)
Physical Examination
Sensitivity and Specificity
58% and 67%
![Page 33: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/33.jpg)
Chest radiography is often necessary to differentiate CAP from other
conditionsCavitation or Multilobar
Occasionally, CXR suggest an etiologic diagnosis.
Pneumatoceles :S. aureus
Upper-lobe cavitating :Tuberculosis
![Page 34: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/34.jpg)
CT is rarely necessary
suspected postobstructive pneumonia caused by a Tumor or
Foreign body
![Page 35: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/35.jpg)
Outpatients
Clinical and Radiologic
usually all that is done before treatment for CAP
since most laboratory results are not available soon enough to influence initial management significantly
![Page 36: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/36.jpg)
Rapid Diagnostic Tests
Influenza virus infection can prompt specific anti-influenza drug treatment and secondary prevention
![Page 37: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/37.jpg)
Etiologic Diagnosis
![Page 38: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/38.jpg)
Exposure to birds
Chlamydia psittaci
![Page 39: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/39.jpg)
Exposure to rabbits
Francisella tularensis
![Page 40: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/40.jpg)
Local influenza activity
Influenza virus
S. pneumoniae
S. aureus
![Page 41: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/41.jpg)
Travel to southwestern United States
Hantavirus
Coccidioides spp.
![Page 42: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/42.jpg)
Dementia, stroke, decreased level of consciousness
Oral anaerobes
Gram-negative enteric bacteria
![Page 43: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/43.jpg)
Severity
Cavitation
Multilobar
![Page 44: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/44.jpg)
Etiologic Diagnosis
Pneumatoceles : S. Aureus
Upper-lobe cavitating : Tuberculosis
![Page 45: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/45.jpg)
CT
Rarely necessary
Postobstructive pneumonia
Tumor or Foreign body
![Page 46: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/46.jpg)
Etiologic Diagnosis
Except for the 2% of CAP patients who are admitted to the ICU
no data exist to show that treatment directed at a specific pathogen is statistically superior to empirical
therapyMycobacterium tuberculosis and influenza
![Page 47: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/47.jpg)
Gram's stain
main purpose of the sputum Gram's stain is to ensure that a sample is suitable for culture
S. pneumoniae, S. aureus, Gram-negative bacteria
![Page 48: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/48.jpg)
Adequate for Culture
>25 Neutrophils
<10 Squamous epithelial cells
per low-power field
![Page 49: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/49.jpg)
Bacteremic Pneumococcal Pneumonia
positive cultures from sputum samples is 50%.
![Page 50: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/50.jpg)
Blood Cultures
Only ~5–14% of cultures of blood from patients hospitalized with CAP are positive, and the
most frequently isolated pathogen is S. pneumoniae
![Page 51: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/51.jpg)
Blood cultures are no longer considered for all hospitalized CAP
patients.
Neutropenia secondary to pneumonia, Asplenia, or Complement deficiencies; Chronic liver disease; or Severe CAP—
should have blood cultured
![Page 52: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/52.jpg)
Antigen Tests
Legionella antigens in urineOnly serogroup 1
Most community-acquiredSensitivity and Specificity
high as 90% and 99%
![Page 53: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/53.jpg)
Antigen Tests
Pneumococcal Urine AntigenSensitive and Specific
80% and >90%False-positive results can be obtained with
samples from pneumococcus-colonized Children
Both tests can detect antigen even after the initiation of appropriate antibiotic therapy
![Page 54: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/54.jpg)
Rapid test for Influenza virus and direct fluorescent antibody tests for
influenza
Respiratory Syncytial Virus; the latter tests are only poorly sensitive
![Page 55: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/55.jpg)
PCR
DNA or RNA
L. Pneumophila
Mycobacteria
M. Pneumoniae
C. Pneumoniae
PCR is generally limited to research studies
![Page 56: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/56.jpg)
Pneumococcal Pneumonia
increased bacterial load documented by PCR is associated with an increased
risk of septic shock, need for mechanical ventilation, and death. Such a test could conceivably help identify patients suitable for ICU
admission.
![Page 57: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/57.jpg)
Serology
A fourfold rise in specific IgM between acute- and convalescent-phase serum is
generally considered diagnostic
Coxiella burnetii
Recently, however, they have fallen out of favor because of the time required to
obtain a final result for the convalescent-phase sample.
![Page 58: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/58.jpg)
Treatment: CAP
Certain patients clearly can be managed at Home, and others clearly require treatment in the
Hospital
![Page 59: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/59.jpg)
S. Pneumoniae
Risk factors for penicillin-resistant :Recent antimicrobial therapy, Age of <2 or >65 years, Attendance at
day-care centers, recent Hospitalization, and HIV
Resistant to Three or more antimicrobial classes with different mechanisms considered MDR
Penicillin ,Macrolides, Tetracyclines, Trimethoprim-sulfamethoxazole
![Page 60: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/60.jpg)
Initial Antibiotic Management
Macrolide + Cephalosporin
or
a Fluoroquinolone alone
![Page 61: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/61.jpg)
Outpatients
Previously healthy and no antibiotics in past 3 months
A macrolide [Clarithromycin (500 mg PO bid) or Azithromycin (500 mg PO once, then 250 mg qd)] or
Doxycycline (100 mg PO bid)
Comorbidities or antibiotics in past 3 months: select an alternative from a different class
A respiratory fluoroquinolone [Moxifloxacin (400 mg PO qd), Gemifloxacin (320 mg PO qd), Levofloxacin (750 mg PO qd)] or
A -lactam [preferred: high-dose Amoxicillin (1 g tid) or Amoxicillin/clavulanate (2 g bid); alternatives: Ceftriaxone (1–2 g IV qd), Cefpodoxime (200 mg PO bid), Cefuroxime (500 mg PO bid)] plus a Macrolidea
In regions with a high rate of "high-level" pneumococcal macrolide resistance,b consider alternatives listed above for patients with comorbidities.
![Page 62: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/62.jpg)
Inpatients, Non-ICU
A respiratory fluoroquinolone [Moxifloxacin (400 mg PO or IV qd), Gemifloxacin (320 mg PO qd), Levofloxacin (750 mg PO or IV qd)]
A -lactamc [Cefotaxime (1–2 g IV q8h), Ceftriaxone (1–2 g IV qd), Ampicillin (1–2 g IV q4–6h), Ertapenem (1 g IV qd in selected patients)] plus a macrolided [oral Clarithromycin or Azithromycin (as listed above for previously healthy patients) or IV azithromycin (1 g once, then 500 mg qd)]
![Page 63: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/63.jpg)
Inpatients, ICU
A -lactame [cefotaxime (1–2 g IV q8h), ceftriaxone (2 g IV qd), ampicillin-sulbactam (2 g IV q8h)] plus
Azithromycin or a fluoroquinolone (as listed above for inpatients, non-ICU)
Special Concerns
If Pseudomonas is a consideration
An antipneumococcal, antipseudomonal -lactam [piperacillin/tazobactam (4.5 g IV q6h), cefepime (1–2 g IV q12h), imipenem (500 mg IV q6h), meropenem (1 g IV q8h)] plus either ciprofloxacin (400 mg IV q12h) or levofloxacin (750 mg IV qd)
The above -lactams plus an aminoglycoside [amikacin (15 mg/kg qd) or tobramycin (1.7 mg/kg qd) and azithromycin]
The above -lactamsfplus an aminoglycoside plus an antipneumococcal fluoroquinolone
If CA-MRSA is a consideration
Add linezolid (600 mg IV q12h) or vancomycin (1 g IV q12h).
![Page 64: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/64.jpg)
aDoxycycline (100 mg PO bid) is an alternative to the macrolide
![Page 65: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/65.jpg)
Management of bacteremic pneumococcal pneumonia
Controversial: nonrandomized studies suggest that combination therapy (especially with a macrolide and a -lactam) is associated with a lower mortality rate than monotherapy, particularly in severely ill
patients. The exact reason is unknown, but possible explanations include an Additive or Synergistic antibacterial effect, Antimicrobial tolerance,
Atypical co-infection, or the Immunomodulatory effects of the macrolides
![Page 66: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/66.jpg)
Duration of treatment for CAPPreviously treated for 10–14 days
Fluoroquinolones and Telithromycin : 5-day course is sufficient for otherwise uncomplicated
CAP.
Even a Single dose of Ceftriaxone has been associated with a significant cure rate.
A longer course is required for patients with bacteremia, metastatic infection, or infection with a
virulent pathogen such as P. aeruginosa or CA-MRSA.
![Page 67: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/67.jpg)
General Considerations
Adequate hydration, oxygen therapy for hypoxemia, and assisted ventilation
severe CAP who remain Hypotensive despite fluid resuscitation may have
adrenal insufficiency and may respond to Glucocorticoid treatment
Immunomodulatory therapy in the form of drotrecogin alfa (activated) should be considered for CAP patients with persistent septic shock and APACHE II scores of
25, particularly if the infection is caused by S. pneumoniae
![Page 68: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/68.jpg)
Failure to Improve
Slow to respond to therapy reevaluated at about day 3 (sooner if is worsening)
Pulmonary edema, Pulmonary embolism, Lung carcinoma, Radiation , Hypersensitivity pneumonitis,
, Connective tissue disease involving the lungs
Resistant to the drug selected, or a sequestered focus (e.g., a lung abscess or empyema)
Also possible that CAP is the correct diagnosis but that an unsuspected pathogen (e.g., CA-MRSA, M.
tuberculosis, or a fungus) is the cause
![Page 69: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/69.jpg)
Complications
Respiratory failure, Shock and Multiorgan failure, Coagulopathy
Metastatic infection, Lung abscess, and complicated Pleural Effusion. Metastatic
infection (e.g., Brain abscess or Endocarditis)
![Page 70: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/70.jpg)
Pleural Effusion
should be tapped for both Diagnostic and Therapeutic purposes.
PH of <7, a Glucose level of <2.2 mmol/L, and a LDH >1000 U/L or if bacteria are seen or cultured, then the
fluid should be drained; a Chest Tube is usually required.
![Page 71: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/71.jpg)
Follow-Up
Fever and Leukocytosis usually resolve 2–4 days
Physical findings may persist longer
CXR may require 4–12 weeks to clear
Age and Underlying lung disease
particularly for elderly patients follow-up radiograph can be done ~4–6 weeks later
relapse or recurrence :particularly in the same lung segment, underlying neoplasm must be considered.
![Page 72: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/72.jpg)
Prognosis
Age, Comorbidities, and site of treatment (inpatient or outpatient)
Young well and usually recover fully after ~2 weeks
Older patients and those with comorbid conditions can take several weeks longer to recover fully
Mortality rate for the outpatient group is <1%
For patients requiring hospitalization, the overall mortality rate is estimated at 10%, with ~50% of
deaths directly attributable to pneumonia.
![Page 73: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/73.jpg)
Prevention
Main preventive measure is Vaccination
Influenza and Pneumococcal
influenza outbreak, vaccinated immediately and given
chemoprophylaxis with either Oseltamivir or Zanamivir for 2 weeks—i.e., until vaccine-induced antibody
levels are sufficiently high
![Page 74: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/74.jpg)
Nosocomial superinfections—both pulmonary and
extrapulmonary—are possible explanations for failure to
improve or worsening
![Page 75: Pneumonia H2012 -Chapter 257](https://reader036.vdocument.in/reader036/viewer/2022062422/56813f57550346895daa23c1/html5/thumbnails/75.jpg)
تشکر با